Literature DB >> 17020818

Lack of association between FCRL3 and FcgammaRII polymorphisms in Japanese type 1 autoimmune hepatitis.

Takeji Umemura1, Masao Ota, Kaname Yoshizawa, Yoshihiko Katsuyama, Tetsuya Ichijo, Eiji Tanaka, Shigeyuki Kawa, Kendo Kiyosawa.   

Abstract

Autoimmune hepatitis (AIH) is an organ-specific autoimmune disease characterized by chronic inflammation of the liver. Although the HLA-DRB1*0405 allele is associated with type 1 AIH in Japanese, the exact genetic etiology of AIH remains undefined. Recently, polymorphisms of Fcgamma receptors (FcgammaR) and Fc receptor-like gene 3 (FCRL3) were linked to a variety of autoimmune diseases, and may be at least partially responsible for susceptibility to AIH. In this study, we genotyped FcgammaRIIA, FcgammaRIIB, and four FCRL3 polymorphisms in 87 Japanese patients with type 1 AIH and 97 ethnically matched controls using the TaqMan assay. Although we were able to detect significantly lower serum IgG concentrations in AIH patients specifically with the FCRL3-110A/A genotype, we observed no difference in the distribution of the genotypes between patients and controls, implying that susceptibility to type 1 AIH in Japanese patients is not influenced by FcgammaRIIA, FcgammaRIIB, or FCRL3 polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020818     DOI: 10.1016/j.clim.2006.08.012

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Clinical significance of immunoglobulin G4-associated autoimmune hepatitis.

Authors:  Takeji Umemura; Yoh Zen; Hideaki Hamano; Satoru Joshita; Tetsuya Ichijo; Kaname Yoshizawa; Kendo Kiyosawa; Masao Ota; Shigeyuki Kawa; Yasuni Nakanuma; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2010-09-23       Impact factor: 7.527

2.  Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome.

Authors:  Ke Li; Peizeng Yang; Min Zhao; Shengping Hou; Liping Du; Hongyan Zhou; Aize Kijlstra
Journal:  Mol Vis       Date:  2009-05-11       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.